logo-loader

Investor Update: Bezant Resources to sell 80% interest in Mankayan copper project

Headlines from the Proactive UK newsroom.

Bezant (LON:BZT) has entered into a conditional deal with a private company based in Singapore to sell an 80% interest in the Mankayan copper-gold project in the Philippines. The deal constitutes a reverse takeover under the Singapore stock exchange rules.

Argentex Group PLC (LON:AGFX), the recently listed provider of foreign exchange services to institutions, corporates and high net worths generated revenues of £9.3mln from 25 June 2019 to 30 September 2019, the period since its admission to Aim. 

Integumen (LON:SKIN) has signed multi-year agreements with two Top 10 global cosmetic companies for recurring use of its LabskinAI services. Research teams in in the US, Asia and the EU will connect and collaborate with the LabskinAI virtual lab.

Genedrive (LON:GDR) has received full ethics approval from the NHS Health Research Authority for the use of its Antibiotic Induced Hearing (AIHL) test in hospital trials. Genedrive believes this represents the world's first ethical approval  for a point-of-care genetic test used to influence neo-natal management in an acute setting.

Maxcyte’s (LON:MXCT) cell engineering technology is to be licensed by Nasdaq-listed genome specialist Editas Medicine. Through the deal, Editas receives non-exclusive clinical and commercial use rights to MaxCyte's platform to develop up to five therapies including four in immuno-oncology. 

HSBC is to slash 10,000 jobs according to a report in the FT this morning. The bank employs 240,000 staff worldwide.

Building materials group SIG has disposed of two divisions for a total of £236mln to shore up its balance sheet in the face of a continued deterioration in construction markets across Europe. Air Handling is being sold for £198mln and Building Solutions for £38mln.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bezant Resources PLC named herein, including the promotion by the Company of Bezant Resources PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 days, 15 hours ago

2 min read